106 related articles for article (PubMed ID: 16192911)
1. Cost effectiveness of positron emission tomography in Canada.
Sloka JS; Hollett PD
Med Sci Monit; 2005 Oct; 11(10):PH1-6. PubMed ID: 16192911
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules.
Cao JQ; Rodrigues GB; Louie AV; Zaric GS
Clin Lung Cancer; 2012 May; 13(3):161-70. PubMed ID: 22133290
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of positron emission tomography in breast cancer.
Sloka JS; Hollett PD; Mathews M
Mol Imaging Biol; 2005; 7(5):351-60. PubMed ID: 16086227
[TBL] [Abstract][Full Text] [Related]
4. Staging non-small lung cancer with positron emission tomography: diagnostic value, impact on patient management, and cost-effectiveness.
Nosotti M; Castellani M; Longari V; Chella B; Baisi A; Rosso L; Santambrogio L
Int Surg; 2008; 93(5):278-83. PubMed ID: 19943430
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.
Nguyen VH; Peloquin S; Lacasse Y
Can Respir J; 2005; 12(1):19-25. PubMed ID: 15776130
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
[TBL] [Abstract][Full Text] [Related]
7. PET/CT in non-small cell lung cancer staging-promises and problems.
Devaraj A; Cook GJ; Hansell DM
Clin Radiol; 2007 Feb; 62(2):97-108. PubMed ID: 17207691
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.
Sloka JS; Hollett PD; Mathews M
Med Sci Monit; 2004 May; 10(5):MT73-80. PubMed ID: 15114279
[TBL] [Abstract][Full Text] [Related]
9. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.
Lejeune C; Bismuth MJ; Conroy T; Zanni C; Bey P; Bedenne L; Faivre J; Arveux P; Guillemin F
J Nucl Med; 2005 Dec; 46(12):2020-8. PubMed ID: 16330566
[TBL] [Abstract][Full Text] [Related]
10. Advances in positron emission tomography technology have increased the need for surgical staging in non-small cell lung cancer.
Lee BE; von Haag D; Lown T; Lau D; Calhoun R; Follette D
J Thorac Cardiovasc Surg; 2007 Mar; 133(3):746-52. PubMed ID: 17320577
[TBL] [Abstract][Full Text] [Related]
11. PET/CT for staging lung cancer: costly or cost-saving?
Buck AK; Herrmann K; Schreyögg J
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):799-801. PubMed ID: 21442260
[No Abstract] [Full Text] [Related]
12. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer.
Meyers BF; Haddad F; Siegel BA; Zoole JB; Battafarano RJ; Veeramachaneni N; Cooper JD; Patterson GA
J Thorac Cardiovasc Surg; 2006 Apr; 131(4):822-9; discussion 822-9. PubMed ID: 16580440
[TBL] [Abstract][Full Text] [Related]
14. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
[TBL] [Abstract][Full Text] [Related]
15. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effective PET investigations in oncology].
Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
[TBL] [Abstract][Full Text] [Related]
17. [Current status of 18F-FDG PET in predicting outcome of cancer therapy].
Gong HY; Yu JM
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):577-80. PubMed ID: 16429617
[No Abstract] [Full Text] [Related]
18. The value of positron emission tomography in patients with non-small cell lung cancer.
Kee F; Erridge S; Bradbury I; Cairns K
Eur J Radiol; 2010 Jan; 73(1):50-8. PubMed ID: 19084367
[TBL] [Abstract][Full Text] [Related]
19. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion.
Halpern BS; Schiepers C; Weber WA; Crawford TL; Fueger BJ; Phelps ME; Czernin J
Chest; 2005 Oct; 128(4):2289-97. PubMed ID: 16236886
[TBL] [Abstract][Full Text] [Related]
20. Value of positron emission tomography for lung cancer staging.
Albes JM; Dohmen BM; Schott U; Schülen E; Wehrmann M; Ziemer G
Eur J Surg Oncol; 2002 Feb; 28(1):55-62. PubMed ID: 11869015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
